Stock & Company Details
Biofrontera Inc $BFRI
Price:
N/A
N/A
15M
$18M
52 Week High:
N/A
10 Day Average Volume:
N/A
-1.12
50 Day Moving Average:
N/A
52 Week Low:
N/A
30 Day Average Volume:
N/A
N/A
N/A
N/A
30 Day Change:
N/A
3 Month Change:
N/A
Health Technology
BFRI technical indicators
Latest Biofrontera Inc (BFRI) indicator readings as of 2026-09-18.
BFRI's 14-day RSI is 46.1, in neutral territory. At $1.32 it is trading 31.0% above its 200-day moving average of $1.01, and above its 50-day average of $1.30. Price sits in the middle of its Bollinger Bands ($1.21 to $1.71). ADX reads 40.8, indicating a trending market.
Select a strategy to see its performance
Backtested on this stock over recent history.
| Strategy | Trend | Return | Win rate |
|---|---|---|---|
| MACD Momentum Momentum Buy when MACD turns positive (crosses above zero) and RSI confirms momentum above 50; sell when MACD falls back below zero. | – | – | |
| RSI Reversal Mean reversion Buy when RSI falls below 30 (oversold), sell when it climbs above 70 (overbought). | – | – | |
| Volatility Breakout Volatility Buy when price closes above the upper Bollinger Band, sell on reversion to the 20-day average. | – | – | |
| Strong-Trend Pullback Trend + timing In strongly trending stocks (ADX above 25), buy short-term dips (Stochastic below 30) and sell into overbought (above 80). | – | – |
Overview
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. Its licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. its licensed product is Ameluz, which is a prescription drug approved for use in combination with the RhodoLED lamp series, for PDT (when used together, Ameluz PDT). including the complementary product BF-RhodoLED, and Xepi.
Finance Bot
Ask your questions
Start by typing a question below.
